We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Sekisui Diagnostics

For 40 years SEKISUI Diagnostics has been committed to providing innovative medical diagnostics to physicians and lab... read more Featured Products: More products

Download Mobile App




Multiple Coagulation Parameters Predict Postoperative Bleeding Volume in Cardiovascular Surgery

By LabMedica International staff writers
Posted on 02 Dec 2021
Print article
Image: The CP3000Automated Coagulation System measures various coagulation factors (Photo courtesy of Sekisui Medical Company)
Image: The CP3000Automated Coagulation System measures various coagulation factors (Photo courtesy of Sekisui Medical Company)
Coagulopathy and massive bleeding are severe complications of cardiovascular surgery, particularly occurring after procedures requiring prolonged cardiopulmonary bypass (CPB). During surgery massive transfusion of blood products may become necessary.

Reliable and predictive laboratory tests on coagulation function will help guide clinicians to appropriate transfusion and possibly decrease variability in transfusion practices. Appropriate coagulation parameters would help to predict bleeding after cardiovascular surgery and measuring multiple coagulation parameters may prove useful.

Medical Laboratorians at the Asahikawa Medical University Hospital (Asahikawa, Japan) and their colleagues in a prospectively study collected cohort of 48 patients undergoing cardiovascular surgery from November 2015 to March 2016. They examined the association between coagulation parameters and bleeding volume. The median age of the cohort was 69 years, 29 males and 19 females and all were ethnically Asian.

The team measured prothrombin time (PT) or activated partial thromboplastin time (APTT) and fibrinogen (Fib) with the Coapresta2000 automated analyzer (coagulation one-stage assay (Sekisui Medical Company, Tokyo, Japan). Activities of coagulation factor II (FII), FV, FVII, FVIII, FIX, FX, FXI and FXII were measured with Sekisui Medical Company’s Coapresta3000. α2 Plasmin inhibitor (α2PI, synthetic substrate assay), antithrombin (AT, synthetic substrate assay), thrombin-antithrombin complex (TAT, chemiluminescent enzyme immunoassay) and FXIII activity (synthetic substrate assay) were measured using the STACIA automated analyzer (LSI Medience Corporation, Tokyo, Japan).

The scientists reported that bleeding volume during surgery was 2,269 (174–10,607) mL. Number of transfusion units during surgery were packed red blood cells 12 (0–30) units, fresh frozen plasma 12 (0–44) units, platelets 20 (0–60) units and intraoperative autologous blood collection 669 (0–4,439) mL. Post-surgery activities of coagulation factors II (FII), FV, FVII, FVIII, FIX, FX, FXI and FXII were decreased. Values of fibrinogen, antithrombin, α2 plasmin inhibitor (α2PI) and FXIII were also decreased. Values of thrombin-antithrombin complex (TAT) were increased. Values of FII, FIX, FXI and α2PI before surgery were negatively correlated with bleeding volume. Level of FIX after surgery was negatively correlated with bleeding volume and level of TAT after surgery was positively correlated with bleeding volume.

The authors concluded that FII, FIX, FXI, FXIII and α2PI are associated with postoperative bleeding volume. Diluted coagulopathy, decrease in stabilized fibrin due to decrease in FXIII and hyperfibrinolysis due to decrease in α2PI may contribute to hemostatic defect. Thrombin burst due to operative stress as represented by increase in TAT values may also contribute to hemostatic defect. The study was published on October 9, 2021 in the Thrombosis Journal.

Related Links:
Asahikawa Medical University Hospital
Sekisui Medical Company
LSI Medience Corporation


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
TRAb Immunoassay
Chorus TRAb

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.